The Roles of MDM2 and MDMX in Cancer

被引：206

作者：

Karni-Schmidt, Orit ^{[1
]}

Lokshin, Maria ^{[1
]}

Prives, Carol ^{[1
]}

机构：

[1] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA

来源：

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 | 2016年 / 11卷

关键词：

cancer; MDM2; MDMX; p53; tumorigenesis; UBIQUITIN LIGASE ACTIVITY; P53-MDM2 FEEDBACK LOOP; SUPPRESSOR TRANSACTIVATION DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION-FACTOR-BINDING; SMALL-MOLECULE INHIBITORS; SQUAMOUS-CELL CARCINOMA; STRUCTURE-BASED DESIGN; STAPLED P53 PEPTIDE; 5S RIBOSOMAL-RNA;

D O I：

10.1146/annurev-pathol-012414-040349

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been shown to exert oncogenic activity. These two proteins are best understood as negative regulators of the p53 tumor suppressor, although they may have additional p53-independent roles. Understanding the dysregulation of MDM2 and MDMX in human cancers and how they function either together or separately in tumorigenesis may improve methods of diagnosis and for assessing prognosis. Targeting the proteins themselves, or their regulators, may be a promising therapeutic approach to treating some forms of cancer.

引用

页码：617 / 644

页数：28

共 50 条

[21] MDM2/MDMX inhibitor peptide: WO2008106507
Macchiarulo, Antonio
Pellicciari, Roberto
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (05) : 721 - 726
[22] Mdm2 and MdmX: Partners in p53 Destruction
Manfredi, James J.
[J]. CANCER RESEARCH, 2021, 81 (07) : 1633 - 1634
[23] Regulation of p63 function by Mdm2 and MdmX
Kadakia, M
Slader, C
Berberich, SJ
[J]. DNA AND CELL BIOLOGY, 2001, 20 (06) : 321 - 330
[24] Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?
Wade, Mark
Wahl, Geoffrey M.
[J]. MOLECULAR CANCER RESEARCH, 2009, 7 (01) : 1 - 11
[25] Mdm2 and MdmX partner to regulate p53
Wang, Xinjiang
Jiang, Xuejun
[J]. FEBS LETTERS, 2012, 586 (10) : 1390 - 1396
[26] Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)
Macchiarulo, Antonio
Giacche, Nicola
Carotti, Andrea
Moretti, Fabiola
Pellicciari, Roberto
[J]. MEDCHEMCOMM, 2011, 2 (06) : 455 - 465
[27] Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain
Ilic, Viktoria K.
Egorova, Olga
Tsang, Ernest
Gatto, Milena
Wen, Yi
Zhao, Yong
Sheng, Yi
[J]. BIOMOLECULES, 2022, 12 (05)
[28] MDM2 and MDMX status as a determinant of in vitro cellular sensitivity to MDM2 antagonists in human tumour cell lines
Lu, X.
Liu, J.
Watson, A.
Hardcastle, I. R.
Griffin, R. J.
Golding, B. T.
Newell, D. R.
Lunec, J.
[J]. EJC SUPPLEMENTS, 2008, 6 (12): : 137 - 137
[29] Micro RNA level changes in prostate cancer cells treated with MDMX and MDM2 inhibitors
Fatirkhorani, Rojin
Alsarrani, Ahmed Saleh
Jaganathan, Shyam Sundar
Natarajan, Umamaheswari
Rathinavelu, Appu
[J]. CANCER RESEARCH, 2024, 84 (06)
[30] Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery
Popowicz, Grzegorz M.
Czarna, Anna
Wolf, Siglinde
Wang, Kan
Wang, Wei
Doemling, Alexander
Holak, Tad A.
[J]. CELL CYCLE, 2010, 9 (06) : 1104 - 1111

← 1 2 3 4 5 →